Clinical Trial Update: Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating vorinostat with pegylated liposomal doxorubicin in relapsed or refractory lymphomas; the study is terminated with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Vorinostat (vorinostat)

Snippet

Sponsor: Yale University | Conditions: Relapsed Lymphomas, Refractory Lymphomas | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-07-27